Zenith Epigenetics Ltd. Competitors

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia

Incyte is focused on advancing biopharmaceutical innovation. Founded in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, Incyte has grown into a global organization with a robust portfolio of treatments across Hematology, Oncology and Inflammation and Autoimmunity. Today, the company has more than 2,800 employees and operations in 13 countries across North America, Europe and Asia. Our goal is to develop breakthrough medicines that improve patients' lives. With patients at the center of everything we do, our discovery approach focuses on building a portfolio of compounds that are scientifically differentiated and poised to make a meaningful impact. At Incyte, we aim to foster a workplace grounded in respect, curiosity and accountability. We are proud to have been named among the Top Employers by Science magazine for 8 consecutive years, as well as being named one of the Global Top 100 Most Loved Workplaces and America’s Top 100 Most Loved Workplaces by Newsweek and the Best Practice Institute. To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. See our Community Guidelines: http://bit.ly/2sV0H5W

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.